ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

GAO Recommends Tighter Policies on NIH Recusals.

June 29, 2007

Congress Agrees On Jackson Lab Support, But does Not Add Money; Earmarks Hit NCI Budget

October 27, 1989

GAO Calls For Stronger FDA Enforcement Of Accelerated Approval Followup Studies

October 30, 2009

President’s Cancer Panel Special Commission On Breast Cancer Named

April 25, 1992

National Action Plan: Steering committee Votes No Confidence In HHS Official.

August 15, 1997

Study: Women at Higher Risk Of Estrogen Receptor Positive Breast Cancer After Smoking

February 28, 2014